NEW! Conversations on Twitter :
-
Great exchange yesterday afternoon on VC confidence in Biotech
Started by @RyanMFierce, with input from VCs, others -
Quick exchange on Alnylam's early study halt
@JohnCFierce started the exchange - FDA approval of HIV prevention drug spurring concerns including risky behavior and compliance
@FierceBiotech: DeCode, Genentech find gene mutation marks protection against Alzheimer's. More | Follow @FierceBiotech
@JohnCFierce: Elan is priced for a buyout deal? Oh, my. Who would buy that company just now? Report | Follow @JohnCFierce
@RyanMFierce: Alnylam up 45% after ALN-TTR02 passes Phase I. Could this be the RNAi drug we've all been waiting for? | Follow @RyanMFierce
> The lucrative business of publishing research papers is about to encounter a serious threat. The European Commission is moving to make all publicly-funded research studies freely available, spurring on an open-access movement that could torpedo the business model of publishers like Reed Elsevier, according to a report from Reuters' Ben Hirschler. Report
> Teva and Active Biotech say that the EMA has accepted their application for the MS drug laquinimod. Active won a $5M milestone based on the regulators' acceptance of the app for review. Release
> Clovis Oncology and Array BioPharma announced an agreement for the discovery of a novel KIT inhibitor targeting resistance mutations for the treatment of GIST. Release
> Ziopharm Oncology has announced a new executive team. Release
Pharma News
@FiercePharma: Simponi for colitis, J&J says: Janssen unit asks FDA to OK new use for Remicade follow-up drug. More | Follow @FiercePharma
> J&J drug sales hold their own, thanks to foreign growth. Report
> AZ puts Brilinta up for another head-to-head fight with Plavix. Article
> Appeals court ruling threatens pay-to-delay deals. News
> Par could fetch up to $2.5B from rival genericsmaker. More
@FierceMedDev: Radiology devicemaker Accuray is buying Morhpormics for $5.7M. Release | Follow @FierceMedDev
@DamianFierce: Biomet has cut back its year-over-year losses due to sales growth in its major divisions. More | Follow @DamianFierce
> Life Technologies expands its Dx business with Navigenics buy. News
> J&J posts flat device sales for Q2. Article
> Ex-Medtronic CEO pulled down $8M in 2012. Story
Pharma Manufacturing News
> Lonza seeks growth in China after securing IP. Story
> Feds get conviction in fake J&J test strips case. More
> India regulator orders Aurobindo, others to close 12 plants. Report
> Hospira blames supplier's bad vials for latest recall. Article
Biotech Research News
> Researchers use gene therapy to treat spinal muscular atrophy. Article
> New 'molecular grenade' used to attack tumor cells. Report
> Researcher rebuts rival finding that ovarian stem cells exist. Story
> Rare gene mutation protects against Alzheimer's. More
> Alnylam generates preclinical buzz with RNAi hemophilia drug. News
And Finally… Some chocolate products may soon come with a label explaining how they can improve blood circulation. Story